23andMe disclosed in an updated filing that it expects to incur between $1M-$2M in onetime expenses related to its previously disclosed data breach incident during Q3, primarily consisting of technology consulting services, legal fees, and expenses of other third-party advisors. The company believes that such expenses and the direct or indirect business impacts of the incident could negatively affect its financial results. The company is not able to predict whether such direct or indirect impacts of the incident could have a material effect on its financial condition and/or results of operations for the fiscal year ending March 31, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ME:
- 23andMe price target lowered to 90c from $1.75 at Citi
- 23andMe price target lowered to $3 from $5 at TD Cowen
- 23andMe launches Total Health, a new health membership
- 23andMe reports updated safety, preliminary efficacy data from Phase 1/2a study
- 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
